Drug Profile
Research programme: ion channel modulators - Novartis/Saniona
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Aniona
- Developer Novartis; Saniona
- Class Neuropsychotherapeutics; Small molecules
- Mechanism of Action Small conductance calcium-activated potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ataxia; Essential tremor
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Essential-tremor in USA
- 28 Sep 2021 No recent reports of development identified for preclinical development in Ataxia in USA
- 25 Jan 2021 Cadent Therapeutics has been acquired and merged into Novartis